Pioneering blood test could help Suffolk air ambulance crews identify brain bleeds before hospital
East Anglian Air Ambulance says early research into a handheld blood test could help critically ill patients reach specialist treatment sooner.
A pioneering blood test being used by air ambulance crews covering Suffolk could help identify patients at risk of serious brain bleeds before they reach hospital, according to new research.
East Anglian Air Ambulance has been testing the technology as part of its BRAIN-FIRST programme, which aims to give emergency doctors and paramedics more information about potentially life-threatening brain injuries while they are treating patients at the scene.
The charity says early findings are encouraging, with the initial study identifying all confirmed cases of bleeding on the brain when two blood markers were considered together.
However, researchers say further work is needed to establish whether the technology improves treatment decisions or patient outcomes.
Dr James Price, a consultant and Clinical Lead for Research and Development at East Anglian Air Ambulance, told us identifying a brain bleed as early as possible could be critical.
"So when someone has a serious bleed in the brain, time can be absolutely critical," he said.
"One of the biggest challenges that we face as pre-hospital clinicians is that when we arrive at the patient's side, we can't actually see what's happening inside their brain."
Currently, doctors and paramedics largely rely on a patient's medical history, symptoms and physical examination to assess whether they may have suffered a brain bleed.
A hospital CT scan is generally needed to confirm the diagnosis.
But the new handheld analyser measures proteins released into the bloodstream following injury to brain cells, providing results within approximately 15 minutes of testing.
Dr Price said the information could help clinicians assess patients earlier.
"What this blood test offers is the possibility of identifying patients who may have a serious brain bleed much, much earlier and while we're still treating them at the scene," he told us.
What has the research found?
The first published BRAIN-FIRST study involved 65 adults with acute non-traumatic coma, who were treated by East Anglian Air Ambulance between January 2025 and April 2026.
All were seriously unwell patients who required advanced emergency care before reaching hospital.
Of those tested, 33 were subsequently confirmed by CT scans to have bleeding inside the skull.
Researchers found that combining the results of two blood markers, known as GFAP and UCH-L1, identified all 33 confirmed cases.
However, the combined approach also produced positive results in 27 of the 32 patients who did not have a brain bleed.
This means the blood test cannot reliably confirm a brain bleed on its own, and CT scans remain necessary for a definitive diagnosis.
The findings, published in the peer-reviewed medical journal JAMA Network Open, suggest the technology could become a useful additional tool for emergency clinicians.
The researchers also found that testing GFAP alone identified 32 of the 33 confirmed cases.
They cautioned that the initial study was relatively small and focused on a specific group of critically ill patients.
Further research will be needed to establish how well the findings apply to other patients with suspected brain injuries.
Could it reduce delays to specialist treatment?
One of the potential benefits being investigated is whether earlier information about a possible brain bleed could help emergency crews decide which hospital a patient should be taken to.
Patients who require specialist neurosurgical treatment may initially be transported to a hospital without those services, before being transferred elsewhere.
East Anglian Air Ambulance hopes that identifying patients at higher risk before they leave the scene could help some receive specialist care more quickly.
Dr Price explained:
"And that can help us make better decisions about which hospital to take them to."
"We can alert specialist teams earlier and potentially avoid delays in getting them the treatment that they need."
He added: "And really it's all about getting the right patient to the right hospital the first time."
The potential to reduce unnecessary hospital transfers could be particularly relevant across rural areas of Suffolk and East Anglia, where access to specialist services may involve longer journeys.
However, the research has not yet demonstrated that the test reduces delays, changes hospital destination decisions or improves survival.
More than 200 patients tested
East Anglian Air Ambulance says its teams have now used the blood test with more than 200 patients with suspected serious brain injuries.
The device, called the i-STAT Alinity, analyses a small blood sample to detect the two proteins associated with brain cell injury.
The charity is now working with ambulance services in the UK and internationally to assess the technology in a larger and more varied group of patients.
It is also developing a second research programme, BRAIN-FIRST2, which will investigate whether combining the blood test with other clinical information could help doctors make more informed treatment decisions.
The original project received financial support from Tony and Maggie Abel, of Abel Homes, which helped fund the testing cartridges used by the analyser.
Dr Price believes the work could represent an important development in how critically ill patients are assessed before reaching hospital.
"I think it's important to say for me, the really exciting thing about Brain First is we're beginning to bring some of the diagnostic capabilities of a hospital directly to the patient side," he told us.
"And actually, if we can identify serious brain injuries earlier, we've got the opportunity to get patients to the right hospital the first time and ultimately give them the best possible chance of recovery."
The research team says larger studies will be needed to determine whether that potential translates into improved care and outcomes for patients.
The initial findings are available in JAMA Network Open.